GLP-1 vs Wegovy vs Ozempic: The Complete Naming Guide

If you're confused about GLP-1, Ozempic, Wegovy, Mounjaro, and Zepbound—you're not alone. The naming of these medications is confusing by design, leading to widespread misunderstanding about what these drugs actually are and who they're for. Let's clear up the confusion once and for all with a straightforward explanation of what these medications are, how they're related, and which one you actually need.

Why the Naming Is So Confusing

The confusion stems from pharmaceutical companies marketing the same medication under different brand names for different FDA-approved uses. This is a common practice in the pharmaceutical industry, but it creates massive confusion for consumers.

Think of It Like This:

Semaglutide: Ozempic vs Wegovy

Semaglutide is a GLP-1 receptor agonist manufactured by Novo Nordisk. It's sold under two brand names:

How Semaglutide Works

Semaglutide mimics GLP-1, a natural hormone your body produces after eating. It:

• Slows gastric emptying (food stays in stomach longer)
• Reduces appetite and food cravings
• Improves insulin secretion when blood sugar is elevated
• Reduces glucagon secretion (glucagon raises blood sugar)
• Acts on brain centers that regulate appetite

These mechanisms lead to both improved blood sugar control AND significant weight loss—which is why the same drug works for both conditions.

Tirzepatide: Mounjaro vs Zepbound

Tirzepatide is a dual GIP/GLP-1 receptor agonist manufactured by Eli Lilly. It's sold under two brand names:

How Tirzepatide Works

Tirzepatide is unique because it activates TWO receptors:

• GLP-1 receptor: Same effects as semaglutide (appetite suppression, slowed digestion, improved insulin)
• GIP receptor: Additional metabolic benefits, may enhance fat breakdown and improve insulin sensitivity

This dual action tends to produce greater weight loss than semaglutide in head-to-head studies, with tirzepatide showing average weight loss of 20-22% vs 15-17% for semaglutide in clinical trials.

FDA Approvals: Diabetes vs Weight Loss

Understanding FDA approvals helps explain the naming confusion and insurance coverage differences.

What FDA Approval Means

Timeline of Approvals

Which One Do You Actually Need?

The answer depends on your goals, medical history, and insurance coverage—but remember, you're really choosing between two active ingredients (semaglutide vs tirzepatide), not four different drugs.

Semaglutide vs Tirzepatide: Which Is Better?

Insurance Coverage Differences

Insurance coverage is where the different brand names create real financial impact.

Typical Coverage Patterns

The Off-Label Workaround

Many people seeking weight loss have successfully obtained insurance coverage for Ozempic or Mounjaro by:

• Having a diagnosis of pre-diabetes or metabolic syndrome (even if weight loss is the primary goal)
• Working with a doctor willing to prescribe for blood sugar management with weight loss as a secondary benefit
• Using manufacturer savings cards to reduce copays

Compounded Versions Explained

Due to ongoing shortages of brand-name GLP-1 medications, the FDA allows compounding pharmacies to create versions of semaglutide and tirzepatide. This has made these medications accessible to millions who couldn't afford brand-name prices.

What Are Compounded Medications?

Reputable Compounded GLP-1 Providers

If you're considering compounded semaglutide or tirzepatide, choose providers that use licensed US compounding pharmacies and offer medical oversight. Our top recommendations:

Quick Reference Guide

Here's everything you need to know at a glance:

The Bottom Line

The confusing naming of GLP-1 medications is largely a marketing and regulatory artifact. What really matters is understanding that:

Don't let the confusing names prevent you from accessing these medications. Focus on finding a reputable provider who can help you choose the right active ingredient (semaglutide vs tirzepatide) and navigate insurance or find affordable compounded alternatives.